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Abstract
Incremental hemodialysis has been examined as a viable hemodialysis regimen for selected end-
stage renal disease (ESRD) patients. Preservation of residual kidney function (RKF) has been the 
driving impetus for this approach given its benefits upon the survival and quality of life of dialysis 
patients. While clinical practice guidelines recommend an incremental start of dialysis in 
peritoneal dialysis patients with substantial RKF, there remains little guidance with respect to 
incremental hemodialysis as an initial renal replacement therapy regimen. Indeed, several large 
population-based studies suggest that incremental twice-weekly vs. conventional thrice-weekly 
hemodialysis has favorable impact upon RKF trajectory and survival among patients with 
adequate renal urea clearance and/or urine output. In this report, we describe a case series of 13 
ambulatory incident ESRD patients enrolled in a university-based center’s Incremental 
Hemodialysis Program over the period of January 2015 to August 2016 and followed through 
December 2016. Among five patients who maintained a twice-weekly hemodialysis schedule vs. 
eight patients who transitioned to thrice-weekly hemodialysis, we describe and compare patients’ 
longitudinal case-mix, laboratory, and dialysis treatment characteristics over time. The University 
of California Irvine Experience is the first systemically examined twice-weekly hemodialysis 
practice in North America. While future studies are needed to refine the optimal approaches and 
the ideal patient population for implementation of incremental hemodialysis, our case-series serves 
as a first report of this innovative management strategy among incident ESRD patients with 
substantial RKF, and a template for implementation of this regimen.
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In end-stage renal disease (ESRD) patients, preservation of residual kidney function (RKF) 
and urine output (UOP) has been associated with better solute clearance and fluid balance, 
as well as greater health-related quality of life and survival.1–11 Indeed, a large proportion of 
incident ESRD patients will have substantial RKF at the time of dialysis initiation, with 45% 
and 16% of patients having an estimated glomerular filtration rate (eGFR) of ≥10 ml/min/
1.73m2 and ≥15ml/min/1.73m2, respectively, at the time of dialysis initiation.12 The reasons 
for high mortality in the first year on HD is unclear.13, 14 Inevitably, these patients will 
experience loss of RKF over time, which occurs more rapidly amongst 
hemodialysis10, 11, 13, 15–17 than peritoneal dialysis patients,18, 19 presumably due to 
episodic renal ischemia from intra-dialytic hypotension and hypovolemia, activation of 
nephrotoxic inflammatory mediators due to exposure to dialysis tubing and 
impurities,10, 18–21 and reduction in uremic substances that serve as the stimulus for 
remaining hyperfunctioning nephrons.22
Recognizing the importance of the preservation of RKF, there has been increasing interest in 
incremental hemodialysis as an innovative approach for initiating hemodialysis amongst 
incident ESRD patients.23–28 For example, in a study of 85 incident hemodialysis patients in 
Shanghai, those who were initiated and maintained on twice-weekly hemodialysis vs. 
conventional thrice-weekly hemodialysis over the entire study period were less likely to 
experience loss of RKF (defined as UOP <200ml/day) over the course of one year.29 In a 
more recent analysis of 23,645 incident US hemodialysis patients, incremental twice-weekly 
vs. conventional thrice-weekly hemodialysis was associated with greater preservation of 
RKF, defined by renal urea clearance and urine volume, after one year.30 An increasing body 
of data also suggests that incremental hemodialysis is associated with equivalent to better 
survival, particularly amongst patients with substantial RKF (renal urea clearance ≥3ml/min/
1.73m2).17, 30, 31
While the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-
KDOQI) Peritoneal Dialysis Adequacy Group recommends consideration of an incremental 
start of dialysis (i.e., less than a “full” dose) in peritoneal dialysis patients with substantial 
RKF, much less has been written about the practical implementation of incremental 
hemodialysis.32, 33 Although NKF-KDOQI Hemodialysis Adequacy Group guidelines 
endorse twice-weekly hemodialysis amongst patients with renal urea clearances (KRU) 
exceeding 3ml/min/1.73m2, it is not per se recommended as an initial treatment strategy 
amongst such patients.32 Thus, to better inform the field, we describe the largest case series 
of a university-based single center’s experience in implementing an Incremental 
Hemodialysis Program among incident ESRD patients.
METHODS
We conducted a retrospective analysis of 13 incident ESRD patients who initiated 
incremental twice-weekly hemodialysis in the outpatient setting over the contemporary 
period of January 2015 to August 2016 at the University California Irvine Dialysis Center in 
Orange, California. (The management of the dialysis facility has recently been transferred to 
Fresenius Medical Care [FMC] under the new designation “FMC University Dialysis Center 
of Orange.”) Among these patients, eight were transitioned to conventional thrice-weekly 
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hemodialysis, whereas the remaining five patients have continued to receive twice-weekly 
hemodialysis at the time of this report (December 2016). In the overall cohort and between 
these two groups, we analyzed socio-demographic characteristics, laboratory parameters, 
dialysis treatment characteristics, and in-center hemodialysis medications at the time of 
dialysis initiation. We additionally compared laboratory parameters and dialysis treatment 
characteristics at the time of dialysis transition among those who transitioned to thrice-
weekly hemodialysis vs. the most recent values (i.e., values at the end of the observation 
period) among those who maintained twice-weekly hemodialysis.
RESULTS
Study Population
The baseline characteristics of the 13 enrolled are presented in Table 1. Their mean age (± 
SD) was 52.7 ± 18.2 years; 39% were female; and 23%, 54%, 15%, and 8% were non-
Hispanic White, Hispanic, Asian, and Pacific Islander, respectively. The most common 
causes of ESRD were diabetic nephropathy (31%) and hypertension (15%), and other 
etiologies included reduced nephron mass due to partial nephrectomy, obstructive 
nephropathy, glomerulonephritis (e.g., membranoproliferative glomerulonephritis, IgA 
nephropathy), chronic interstitial nephritis, cystic disease (e.g., tuberous sclerosis), and 
congenital renal dysplasia (e.g., solitary kidney) (Figure 1). A large proportion of patients 
were diagnosed with hypertension (85%), diabetes (54%), and cardiovascular disease (31%). 
At the time of dialysis initiation, 46% of patients were using an arteriovenous fistula, and 
54% patients were using a tunneled dialysis catheter as their primary vascular access. The 
average initial hemodialysis session length was 164 ± 34 minutes, and 31%, 8%, 46%, and 
15% of patients were receiving 2–<2.5 hours, 2.5–<3.0 hours, 3.0–<3.5 hours, and 3.5–4.0 
hours of treatment per session, respectively.
Among patients who eventually transitioned to thrice-weekly hemodialysis (N=8), the mean 
± SD, median (IQR), and minimum-maximum duration of their twice-weekly hemodialysis 
regimens were 8.0 ± 3.9 months, 4.5 (5.0, 9.5) months, and 4.0–15.5 months, respectively. 
The two primary indications for transitioning to thrice-weekly hemodialysis were problems 
with (1) excessive interdialytic weight gain (N=4) and (2) inability to achieve adequate total 
clearance (N=4) (Figure 2). Among patients who experienced excessive interdialytic weight 
gain, one patient developed new onset systolic heart failure and three patients developed 
frank volume overload. Among patients with inadequate total clearance, the following 
laboratory aberrancies were observed: hyperkalemia (serum potassium >5.3mmol/L; N=3), 
metabolic acidosis (serum bicarbonate <20mmol/L; N=2), inadequate dialytic clearance per 
session (N=4), and hyperphosphatemia (serum phosphorus >6mg/dl; N=2). Among patients 
who maintained a twice-weekly hemodialysis regimen (N=5), the mean ± SD, median 
(IQR), and minimum-maximum duration of their twice-weekly hemodialysis regimens were 
12.0 ± 6.3 months, 5.0 (9.0, 14.0) months, and 5.5–22.0 months, respectively.
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Comparison of Case-Mix Characteristics of Patients Who Maintained Twice-Weekly vs. 
Transitioned to Thrice-Weekly Hemodialysis Regimens
At the time of dialysis initiation, compared to patients who maintained twice-weekly 
hemodialysis (N=5), those who transitioned to thrice-weekly hemodialysis over the 
observation period (N=8) tended to be older (mean ± SD ages 54 ± 17 vs. 51 ± 21 years, 
respectively) and had a higher proportion of females (50% vs. 20%, respectively). Between 
the two groups, there were similar proportions of patients who were non-Hispanic White 
(25% vs. 20%, respectively), Hispanic (50% vs. 60%, respectively), and Asian/Pacific 
Islander (25% vs. 20%, respectively). Compared to patients who maintained twice-weekly 
schedules, those who transitioned to thrice-weekly hemodialysis had a higher prevalence of 
diabetes (63% vs. 40%, respectively), hypertension (88% vs. 80%, respectively), and 
cardiovascular disease (38% vs. 20%, respectively). Fifty percent of the patients who 
transitioned to thrice-weekly hemodialysis had diabetes as their etiology of ESRD, whereas 
those who were maintained on twice-weekly dialysis had non-diabetic etiologies of ESRD 
only (Figure 1). In comparison to twice-weekly patients, thrice-weekly patients had a higher 
prevalence of tunneled dialysis catheters as their primary vascular access at the time of 
dialysis initiation (63% vs. 40%, respectively), an observation that persisted at the time of 
review of the most recent characteristics (37% vs. 20% of thrice-weekly vs. twice-weekly 
patients, respectively).
Comparison of Laboratory Characteristics of Patients Who Maintained Twice-Weekly vs. 
Transitioned to Thrice-Weekly Hemodialysis Regimens
A comparison of the initial laboratory characteristics among patients who remained on a 
twice-weekly hemodialysis regimen vs. those who eventually transitioned to conventional 
thrice-weekly hemodialysis showed notable differences (Table 2). Compared to patients who 
remained on twice-weekly hemodialysis, those who transitioned to thrice-weekly 
hemodialysis tended to have higher serum potassium (4.7 ± 1.0 vs. 3.7 ± 0.6mmol/L, 
respectively) and lower serum sodium levels (134 ± 4 vs. 139 ± 2mmol/L, respectively). In 
terms of mineral bone disease parameters, compared to twice-weekly hemodialysis patients, 
thrice-weekly patients had higher parathyroid hormone (766 ± 1154 vs. 525 ± 422pg/ml, 
respectively), lower serum phosphorus (5.5 ± 1.5 vs. 6.3 ± 1.6mg/dl, respectively), and 
higher serum calcium levels (8.6 ± 0.7 vs. 8.0 ± 1.1mg/dl, respectively). With respect to 
anemia parameters, they were also observed to have lower hemoglobin (8.6 ± 0.7 vs. 9.9 
± 1.1g/dl, respectively), lower iron saturation (23 ± 10 vs. 26 ± 18%, respectively), and 
higher serum ferritin levels (421 ± 288 vs. 233 ± 226ng/ml, respectively). In terms of 
nutritional markers, they had lower serum albumin (3.3 ± 0.4 vs. 3.5 ± 0.7g/dl, respectively) 
and serum creatinine levels (6.6 ± 2.4 vs. 7.2 ± 1.1mg/dl, respectively).
When the most recent laboratory values of patients who remained on twice-weekly 
hemodialysis were compared to those who transitioned to thrice-weekly dialysis at the time 
of dialysis transition, those on thrice-weekly treatment persisted in having higher serum 
potassium (5.3 ± 0.8 vs. 4.3 ± 0.5mmol/L, respectively), higher parathyroid hormone (661 
± 946 vs. 526 ± 414pg/ml, respectively), lower hemoglobin (9.2 ± 1.0 vs. 10.7 ± 1.1g/dl, 
respectively), and lower iron saturation levels (17 ± 4 vs. 37 ± 23%) (Table 3).
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Comparison of Dialysis Treatment Characteristics of Patients Who Maintained Twice-
Weekly vs. Transitioned to Thrice-Weekly Hemodialysis Regimens
Differences in the initial dialysis treatment characteristics between the two groups were also 
observed (Table 2). Compared to patients who remained on twice-weekly hemodialysis, 
those who transitioned to thrice-weekly hemodialysis tended to have higher interdialytic 
weight gain (1.2 ± 0.6 vs. 0.9 ± 0.7kg, respectively) and higher pre-dialysis blood pressures 
(156 ± 18 vs. 151 ± 27mmHg, respectively). In terms of dialysis prescriptions, compared to 
twice-weekly patients, thrice-weekly patients had longer dialysis session lengths (173 ± 27 
vs. 150 ± 42minutes, respectively) and greater use of dialysate with lower potassium 
concentrations (i.e., at initiation 75% of thrice-weekly patients were treated with a 2K 
dialysate bath whereas 100% of twice-weekly patients were treated with a 3K dialysate 
bath).
Compared to the most recent values of the twice-weekly group, the thrice-weekly group’s 
characteristics at the time of transition showed similar interdialytic weight gain (2.6 ± 1.8 vs. 
2.6 ± 0.9kg, respectively), pre-dialysis blood pressures (161 ± 16 vs. 156 ± 17mmHg, 
respectively), and dialysis session lengths (~3.0 hours across both groups) (Table 3).
Changes in Characteristics over Time among Patients Who Transitioned to Thrice-Weekly 
Hemodialysis
Among patients who eventually transitioned to thrice-weekly hemodialysis, baseline 
characteristics at the time of initiation of twice-weekly dialysis vs. those at the time of 
transition to thrice-weekly hemodialysis are outlined in Tables 2 and 3. Over time, higher 
serum potassium levels were observed (5.3 ± 0.8 vs. 4.7 ± 1.0mmol/L, respectively). In 
terms of mineral bone disease parameters, they developed higher serum phosphorus (6.3 
± 2.3 vs. 5.5 ± 1.5mg/dl, respectively), lower parathyroid hormone (661 ± 946 vs. 766 
± 1154pg/ml, respectively), and maintained similar calcium levels (8.5 ± 0.8 vs. 8.6 
± 0.7mg/dl, respectively). In terms of anemia parameters, they had higher hemoglobin (9.2 
± 1.0 vs. 8.6 ± 0.7g/dl, respectively), lower iron saturation (17 ± 4 vs. 23 ± 10%, 
respectively), and higher ferritin levels over time (535 ± 431 vs. 421 ± 288ng/ml, 
respectively). In terms of nutritional parameters, they had higher serum albumin (3.7 ± 0.3 
vs. 3.3 ± 0.4g/dl, respectively) and higher serum creatinine levels over time (9.2 ± 2.5 vs. 6.6 
± 2.4mg/dl, respectively). With respect to dialysis treatment characteristics, they had higher 
interdialytic weight gain (2.6 ± 1.8 vs. 1.2 ± 0.6kg, respectively), higher pre-dialysis blood 
pressure (161 ± 16 vs. 156 ± 18mmHg, respectively), longer dialysis session length (189 
± 29 vs. 173 ± 27minutes, respectively), and greater use of dialysate with lower potassium 
concentrations (i.e., 2K dialysate baths) (75% vs. 25%, respectively) over time.
Changes in Characteristics over Time among Patients Who Maintained Twice-Weekly 
Hemodialysis
Baseline characteristics at the time of initiation compared to the most recent values among 
patients maintained on a twice-weekly hemodialysis regimen are shown in Tables 2 and 3. 
Similar to those converted to thrice-weekly dialysis, serum potassium concentrations rose 
albeit to lower levels (4.3 ± 0.5 vs. 3.7 ± 0.6mmol/L, respectively). In terms of mineral bone 
disease parameters, they developed higher serum phosphorus (6.3 ± 2.3 vs. 5.5 ± 1.5mg/dl, 
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respectively), lower parathyroid hormone (661 ± 946 vs. 766 ± 1154pg/ml, respectively), 
and maintained similar calcium levels (8.5 ± 0.8 vs. 8.6 ± 0.7mg/dl, respectively). In terms 
of anemia parameters, they had higher hemoglobin (9.2 ± 1.0 vs. 8.6 ± 0.7g/dl, respectively), 
lower iron saturation (17 ± 4 vs. 23 ± 10%, respectively), and higher ferritin levels over time 
(535 ± 431 vs. 421 ± 288ng/ml, respectively). In terms of nutritional parameters, they had 
higher serum albumin (3.7 ± 0.3 vs. 3.3 ± 0.4g/dl, respectively) and higher serum creatinine 
levels over time (9.2 ± 2.5 vs. 6.6 ± 2.4mg/dl, respectively). With respect to dialysis 
treatment characteristics, they had higher interdialytic weight gain (2.6 ± 1.8 vs. 1.2 ± 0.6kg, 
respectively), higher pre-dialysis blood pressure (161 ± 16 vs. 156 ± 18mmHg, 
respectively), longer dialysis session length (189 ± 29 vs. 173 ± 27minutes, respectively), 
and greater use of dialysate with lower potassium concentrations (i.e., 2K dialysate baths) 
(75% v. 25%, respectively) over time.
DISCUSSION
In this report, we describe the largest case series of ambulatory incident ESRD patients 
enrolled in a university-based Incremental Hemodialysis Program. Over a 23-month follow 
up period, 13 patients initiated incremental hemodialysis, among whom eight patients 
eventually transitioned to thrice-weekly hemodialysis and five patients have continued on a 
twice-weekly hemodialysis regimen.
In this descriptive evaluation, we observed that patients who transitioned to conventional 
thrice-weekly hemodialysis had a higher comorbidity burden (e.g., diabetes, hypertension, 
cardiovascular disease) compared to their counterparts who maintained twice-weekly 
hemodialysis. Notably, half of the patients who transitioned to thrice-weekly hemodialysis 
had diabetic nephropathy as the underlying cause of their ESRD compared to none of those 
who were maintained on a twice weekly regimen. This is consistent with observations in 
pre-dialysis chronic kidney disease patients and incident hemodialysis patients in whom 
diabetic nephropathy is associated with faster kidney function decline vs. non-diabetic 
etiologies.34, 35
Those who eventually transitioned to thrice-weekly hemodialysis had mildly worse 
metabolic status (e.g., hyperkalemia, hyponatremia), mineral bone disease parameters (e.g., 
higher parathyroid hormone levels), hematologic values (e.g., lower hemoglobin, lower iron 
saturation), malnutrition-inflammation-complex characteristics (e.g., lower serum albumin, 
lower serum creatinine, higher serum ferritin), and fluid balance (e.g., higher interdialytic 
weight gain, higher pre-dialysis blood pressure) than those remaining on twice-weekly 
hemodialysis.
We did not have access to data on serial renal urea clearance and urine output measurements 
over time. While it is possible that, compared to the twice-weekly group, the thrice-weekly 
patients may have had lower baseline RKF and faster decline over time, behavioral factors 
such as compliance with diet, medications, and dialysis treatments may also have 
contributed to these initial differences and eventual transition to more frequent hemodialysis. 
Longitudinal follow up of these patients also showed that, compared to the twice-weekly 
group’s most recent values, the thrice-weekly group’s values at the time of transition 
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continued to show worse metabolic (e.g. hyperkalemia), mineral bone disease (e.g., higher 
parathyroid hormone), and anemia parameters (e.g., lower hemoglobin and iron saturation). 
Although updated fluid status parameters showed that average interdialytic weight gain and 
pre-dialysis blood pressures were similar across the two groups, excessive fluid gain was 
cited as an indication for transitioning to more frequent hemodialysis among 50% of the 
thrice-weekly patients.
Beyond the NKF-KDOQI’s recommendations regarding a requisite amount of RKF (i.e., 
renal urea clearance of >3ml/min/1.73m2), there are limited data on the optimal 
subpopulations and patient characteristics for the implementation of incremental 
hemodialysis.25 Experts have proposed criteria that can be used to select appropriate patients 
for the incremental hemodialysis regimen,25 including those with (1) renal urea clearance 
>3ml/min/1.73m2 AND (2) urine output >500ml/day, as well as five additional criteria: (a) 
limited fluid retention between two consecutive hemodialysis treatments with an 
interdialytic weight gain <2.5kg, or <5% of the ideal dry weight without hemodialysis for 
three to four days; (b) limited or readily manageable cardiovascular or pulmonary symptoms 
without excessive fluid overload; (c) infrequent or readily manageable hyperphosphatemia; 
(d) ESA-responsiveness and an absence of profound anemia (hemoglobin <8g/dl); (e) 
suitable body size, particularly if not hypercatabolic; (f) infrequent or readily manageable 
hyperkalemia; (g) adequate nutritional status without hypercatabolism; (h) infrequent 
hospitalization and easily manageable comorbidities; and (i) adequate health-related quality 
of life.
At this time, there remain multiple questions with respect to the practical implementation of 
incremental hemodialysis among incident ESRD patients, such as (1) What is the optimal 
dialysis prescription for incremental hemodialysis?; (2) Beyond assessing quarterly renal 
urea clearance as per the NKF-KDOQI Hemodialysis Adequacy Group guidelines, are there 
additional accurate and efficient tools that can be used to serially monitor patients’ RKF?; 
(3) What adjunctive management strategies (i.e., medications, diet, physical activity) can be 
concurrently implemented with incremental hemodialysis to best preserve RKF?; (4) What 
characteristics predict patients who will be able to maintain incremental hemodialysis vs. 
eventually transition to thrice-weekly hemodialysis?; (5) What are the optimal transition 
points for escalation from twice- to thrice-weekly hemodialysis?; and (6) Does the 
incremental hemodialysis regimen provide a more cost-effective management strategy than 
conventional hemodialysis?
Our report has several limitations which bear acknowledgement. First, we lacked data on 
baseline and longitudinal renal urea clearance and urine output data that could be correlated 
with patients’ characteristics and trajectories towards escalation to thrice-weekly vs. 
continuation of twice-weekly hemodialysis. Second, due to data limitations, we were unable 
to examine and compare relevant outcomes such as health-related quality of life, 
hospitalization, and mortality risk amongst patients in the Incremental Hemodialysis 
Program; they are being examined in corollary studies. Third, given that our case-series was 
restricted to a single university-based center with experience in the implementation of 
incremental hemodialysis, our findings may not be generalizable to other patient 
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populations. However, we aspire for our experience to serve as a template for the broader 
implementation of incremental hemodialysis across other medical centers.
In conclusion, we describe a novel strategy for initiating hemodialysis among incident 
ESRD patients as a means to preserve RKF in this population. Future studies are needed to 
refine the optimal approaches for implementation of the incremental twice-weekly 
hemodialysis regimen, as well as the ideal patient populations for this management strategy.
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Figure 1. 
Causes of end-stage renal disease (ESRD) among patients who remained on twice-weekly 
hemodialysis (N=5) and those who escalated to thrice-weekly hemodialysis (N=8)
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Figure 2. 
Indications for escalating to thrice-weekly hemodialysis among eight patients. *Note: 
patients may have had multiple concomitant indications for transition to thrice-weekly 
hemodialysis.
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